Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

How To Play The New Hawkish Fed

Published 06/13/2018, 04:28 AM
Updated 07/09/2023, 06:31 AM

The FOMC is poised to raise the Fed funds target rate by a quarter point in about an hour. And this is with over 95% certainty as this morning's PPI inflation data came in hotter than expected.

But what market players will be most focused on is the "dot plot" of the pace of future hikes. Will they show that two more rate increases are more likely this year?

Or will they show that some committee members think the economic growth and inflation data warrant 3 more hikes?

In the video that accompanies this article, I go over the market psychology of large investors and why any fear-driven stock market sell-off about the Fed's views should be seized as a buying opportunity.

In addition to explaining the things that investors are worried about, like a flattening yield curve and rising inflation data, I give my 3 probability-weighted scenarios for the stock market's reaction.

I also share some wisdom from one of my favorite economists, Brian Wesbury of First Trust.

While I have been an astute Fed-watcher for a couple of decades, I'm leaning on Brian here to help us navigate what level of interest rates this economy can handle and still support expansion and investor optimism.

I come away completely confident in my conclusion to buy whatever sell-off unfolds over the coming days, or weeks.

And some of my favorite stock targets will be Alibaba (NYSE:BABA) , Lam Research (NASDAQ:LRCX) , Centene (NYSE:CNC) , and Edwards Lifesciences (NYSE:EW) , the latter two which have been making great new all-time highs this month.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

I may even add some more CRISPR Therapeutics (NASDAQ:CRSP) as the fear about "gene editing gone wrong" gets over-done.

Disclosure: I own BABA and LRCX shares for the Zacks TAZR Trader portfolio and CNC, EW, and CRSP for the Zacks Healthcare Innovators portfolio.

Kevin Cook is a Senior Stock Strategist for Zacks Investment Research where he runs the TAZR Trader and Healthcare Innovators services. Click "Follow Author" above to receive his latest stock research and macro analysis.

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>



Alibaba Group Holding Limited (BABA): Free Stock Analysis Report

Edwards Lifesciences Corporation (EW): Free Stock Analysis Report

Centene Corporation (CNC): Free Stock Analysis Report

Lam Research Corporation (LRCX): Free Stock Analysis Report

CRISPR THERAPTC (CRSP): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.